Closed · RFA-AI-19-025 · CFDA 93.855 · Discretionary

U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (U01 Clinical Trial Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $250K
Award range
Closed
Status
July 26, 2019
Close date
-
Expected awards

The verdict

U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (U01 Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $250,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $250K
award range
Closed
application status
93.855
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

U.S.-South Africa Program for Collaborative B… is closed (last close July 26, 2019). The parent program page for CFDA 93.855 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed July 26, 2019

Posted Mar 15 Closes Jul 26

Instrument

Cooperative Agreement

Description

The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include: tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. This opportunity is specifically designed to promote partnerships between eligible NIH Intramural Research Program (IRP) investigators (e.g. those conducting research within the laboratories and clinics of the NIH) and eligible South African investigators (e.g., those conducting research in eligible laboratories in South Africa). In order to be eligible for this program, the application must include at least one NIH IRP investigator serving as a Project Scientist with an equal role in the conceptualization, design and execution of the research.

Catch-all / unrestricted eligibility mark · RFA-AI-19-025

Grants.gov marks U.S.-South Africa Program for Collaborative B… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). Only 187 other National Institutes of Health listings share this exact eligibility-code string (2% of 12,420).

Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Parent Grant Program

CFDA 93.855

Allergy, Immunology, and Transplantation Research

National Institutes of Health

View program →

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

U.S.-South Africa Program for Collaborative B… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.855 may publish future NOFOs under the same assistance listing. Open program
  • Allergy, Immunology, and Transplantation Rese… indexes 67 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants